stockportfolio.pro
Moderna, Inc. (MRNA)
Healthcare · Biotechnology · NasdaqGS
Moderna, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $108.40M | $205.82M | $135.07M | $60.00M | $803.00M | $18.47B | $19.26B | $6.85B | $3.24B | $1.94B |
| Gross profit | — | — | — | — | $795.00M | $15.85B | $13.85B | $2.15B | $1.77B | $1.08B |
| Net income | $-216.21M | $-255.92M | $-384.73M | $-514.00M | $-747.00M | $12.20B | $8.36B | $-4.71B | $-3.56B | $-2.82B |
| Net margin | -199.5% | -124.3% | -284.8% | -856.7% | -93.0% | 66.1% | 43.4% | -68.8% | -110.0% | -145.2% |
Source: Moderna, Inc. SEC filings (10-K).
Explore 10 years of Moderna, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MRNA in your portfolio →
Moderna, Inc. financial history by metric
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna, Inc. — frequently asked questions
What is Moderna, Inc.'s revenue?
Moderna, Inc. (MRNA) reported revenue of $1.94B for fiscal year 2025, down 39.9% from the prior year, according to its SEC filings.
Is Moderna, Inc. profitable?
No — MRNA reported a net loss of $-2.82B in fiscal 2025.
What is MRNA's P/E ratio?
Moderna, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Moderna, Inc. growing?
MRNA's revenue grew at roughly 19.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Moderna, Inc. have?
As of fiscal year 2025, MRNA carried roughly $590.00M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Moderna, Inc.'s gross margin?
MRNA's gross margin was 55.3% in fiscal 2025 — gross profit of $1.08B on revenue of $1.94B.
What is Moderna, Inc.'s market cap?
Moderna, Inc. (MRNA) has a market capitalization of about $18.94B, based on the latest data in our nightly-refreshed cache.
When does Moderna, Inc.'s fiscal year end?
MRNA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Moderna, Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.